Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SLN360 in participants with elevated lipoprotein(a) at high risk of ASCVD events
2022-001876-32Phase 2Completed
- Sponsor
- Silence Therapeutics
- Start
- Sep 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lipoprotein(a) hyperlipoproteinemia (Lp(a)) and atherosclerotic disease comparing SLN360 with Placebo (2 arms). Primary endpoint: Time-averaged change in Lp(a) from baseline to Week 36. Started Sep 2022; status: completed.
02
Drugs
zerlasiran
03
Conditions
lipoprotein(a) hyperlipoproteinemia (Lp(a))atherosclerotic disease
Beyond the preview
Go deeper on 2022-001876-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001876-32.